KRAS and neoplasm: While these data are encouraging evidence that dual MEK and ERK inhibition may enable stronger sustained anti-tumor activity in MAPK-addicted tumors, Kras mutant GEM tumors do not regress completely and mice do eventually succumb to their tumors despite continuous treatment.